UNIGE document Scientific Article
previous document  unige:32290  next document
add to browser collection

Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells

Chapman, Rosamund
Shephard, Enid
Stutz, Helen
Douglass, Nicola
Sambandamurthy, Vasan
Ryffel, Bernhard
Jacobs, William
show hidden authors show all authors [1 - 9]
Published in PloS one. 2012, vol. 7, no. 3, e32769
Abstract A safe and effective HIV vaccine is required to significantly reduce the number of people becoming infected with HIV each year. In this study wild type Mycobacterium bovis BCG Pasteur and an attenuated pantothenate auxotroph strain (BCGΔpanCD) that is safe in SCID mice, have been compared as vaccine vectors for HIV-1 subtype C Gag. Genetically stable vaccines BCG[pHS400] (BCG-Gag) and BCGΔpanCD[pHS400] (BCGpan-Gag) were generated using the Pasteur strain of BCG, and a panothenate auxotroph of Pasteur respectively. Stability was achieved by the use of a codon optimised gag gene and deletion of the hsp60-lysA promoter-gene cassette from the episomal vector pCB119. In this vector expression of gag is driven by the mtrA promoter and the Gag protein is fused to the Mycobacterium tuberculosis 19 kDa signal sequence. Both BCG-Gag and BCGpan-Gag primed the immune system of BALB/c mice for a boost with a recombinant modified vaccinia virus Ankara expressing Gag (MVA-Gag). After the boost high frequencies of predominantly Gag-specific CD8(+) T cells were detected when BCGpan-Gag was the prime in contrast to induction of predominantly Gag-specific CD4(+) T cells when priming with BCG-Gag. The differing Gag-specific T-cell phenotype elicited by the prime-boost regimens may be related to the reduced inflammation observed with the pantothenate auxotroph strain compared to the parent strain. These features make BCGpan-Gag a more desirable HIV vaccine candidate than BCG-Gag. Although no Gag-specific cells could be detected after vaccination of BALB/c mice with either recombinant BCG vaccine alone, BCGpan-Gag protected mice against a surrogate vaccinia virus challenge.
Keywords AIDS Vaccines/administration & dosage/genetics/immunologyAnimalsBCG Vaccine/administration & dosage/genetics/immunologyCD8-Positive T-Lymphocytes/immunology/metabolismEnzyme-Linked Immunosorbent AssayGene Products, gag/genetics/immunologyHIV Infections/immunology/metabolism/prevention & controlHIV-1/genetics/immunologyImmunization, Secondary/methodsInterferon-gamma/immunology/metabolismInterleukin-6/immunology/metabolismMiceMice, Inbred BALB CMice, SCIDMycobacterium bovis/genetics/immunology/metabolismPantothenic Acid/metabolismSpleen/cytology/immunology/metabolismTumor Necrosis Factor-alpha/immunology/metabolismVaccination/methodsVaccinia virus/genetics
PMID: 22479338
Full text
Article (Published version) (995 Kb) - public document Free access
Research group Rôles des cytokines de la famille du TNF dans les infections mycobactériennes (500)
Swiss National Science Foundation: 3200A0-118196
(ISO format)
CHAPMAN, Rosamund et al. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells. In: PloS one, 2012, vol. 7, n° 3, p. e32769. doi: 10.1371/journal.pone.0032769 https://archive-ouverte.unige.ch/unige:32290

520 hits



Deposited on : 2013-12-17

Export document
Format :
Citation style :